

**An Important Message from
The Texas Health and Human Services Commission (HHSC)**

**Wegovy Clinical Prior Authorization Criteria Revision
Implements May 2, 2025**

Background:

HHSC implemented the Wegovy (semaglutide) clinical prior authorization on Dec. 27, 2024. The Texas Drug Utilization Review Board prior authorization approved the criteria on Oct. 25, 2024.

Key Details:

On May 2, 2025, HHSC will revise the Wegovy clinical prior authorization. Wegovy is approved for indication of risk reduction of major adverse cardiovascular events in adults with established cardiovascular disease only. The revised version will approve for the above indication if combined with reduced calorie diet and increased physical activity. The verification of the combination will be checked manually.

Action:

The Wegovy clinical prior authorization is mandatory for MCOs. MCOs must implement the revised criteria **by May 2, 2025**.

Resources:

Wegovy clinical prior authorization criteria document: paxpress-txpa.acentra.com/wegovy.pdf

Questions?

Please contact UnitedHealthcare Customer Service at 888-887-9003, 8 a.m.–6 p.m. CT, Monday–Friday.